Athira's alternative Alzheimer's approach runs into a PhII brick wall - Endpoints News

Athira Pharma reported another setback Wednesday as its mid-stage Alzheimer’s study failed, becoming the latest biotech to come up short in the disease. The Seattle-area company said the Phase II trial comparing its lead candidate fosgonimeton, formerly ATH-1…

PTC Therapeutics’ years-long effort to push its controversial Duchenne MD drug Translarna into the US has just run into its latest setback. The biotech reported a mixed set of data from their confir… [+682 chars]

full article...